ANAkriti Naraen

Akriti Naraen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Akriti Naraen has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Conduction system pacing in extensive left conduction disease and prior ablation of the right bundle branch

    by Mohamed Zuhair, Akriti Naraen, Ian Wright, Nandita Kaza, Ahran D Arnold, Zachary Whinnett, Daniel Keene MbCHb MSc

    This case report presents the successful implantation of a left bundle area pacing lead in a 64-year-old male with a history of bundle branch ventricular tachycardia and consequent therapeutic ablation of the right bundle branch. Despite extensive conduction disease, effective physiological pacing was achieved as part of a cardiac synchronisation pacing

  • Open Access

    Physiological pacing: mechanisms, clinical indications, and perspectives

    by Zachary Whinnett, Akriti Naraen, Pugazhendhi Vijayaraman, John G F Cleland, Daniel Keene

    Normal cardiac function depends on a highly efficient cardiac conduction system. Conduction system disease impairs cardiac function, which can reduce exercise capacity, cause symptoms such as breathlessness and fatigue, and, if severe, result in syncope and death. Pacemakers were originally developed to treat profound bradycardia caused by complete heart block. However, pacing the right ventricle leads to non-physiological activation of the ventricular myocardium, reducing global cardiac performance. Early developments in physiological pacing focused on promoting intrinsic activation, delivering more physiological heart rate responses during exercise, and co-ordinating atrial and ventricular activation. More recently, the focus has shifted to delivering pacing which preserves or restores normal ventricular activation patterns, including atrio-biventricular pacing, conduction system pacing by His-bundle pacing, left bundle branch pacing, left septal pacing, and Bachmann’s bundle pacing. Adoption of these more physiological approaches might reduce the adverse effects of pacing, as well as expanding pacing indications to treatment of other forms of conduction system disease. This paper reviews the evolving field of physiological pacing.


  • Open Access

    An in silico guide for ventriculo-ventricular delay programming for left bundle branch-optimized cardiac resynchronization therapy

    by Marina Strocchi, Jack W Samways, Akriti Naraen, Nadine Ali, Matthew J Shun-Shin, Karli Gillette, Christopher Aldo Rinaldi, Ahran D Arnold, Gernot Plank, Edward J Vigmond, et al.

    Aims: Left bundle branch pacing (LBBP)–optimized cardiac resynchronization therapy (LOT-CRT) can improve left ventricular (LV) activation when LBBP alone or conventional biventricular pacing are ineffective. However, the optimal programming settings for ventriculo-ventricular delay (VVD) for LOT-CRT are unknown. We aim to investigate how to optimally program VVD for LOT-CRT in the presence of various LV conduction substrates using computational modelling. Methods and results: We simulated ventricular activation on 24 anatomies and validated the model against clinical data. Diffuse LV conduction system and intra-myocardial delay were simulated by slowing the conduction velocity of the LV His-Purkinje system and myocardium, respectively, alone or in combination with proximal left bundle branch block (LBBB). We simulated LOT-CRT with selective or myocardial capture (LV septal pacing, LVSP) with VVD ranging between −100 ms (LBBP/LVSP ahead) and +100 ms [LV epicardial lead (LVepiP), ahead]. Response was quantified with 95% LV activation times (LVAT95). In the presence of diffuse LV conduction system delay, the optimal VVD for LOT-CRT was always negative (LBBB: −42.5 ± 6.6 ms; no LBBB: −36.2 ± 5.6 ms), as delivering LBBP ahead of LVepiP compensates for the slow LV His-Purkinje. In the presence of LV intra-myocardial disease, the shortest LVAT95 with LOT-CRT was achieved by pacing the coronary sinus LV first (optimal VVD for LBBB: 23.3 ± 8.5 ms; no LBBB: 79.2 ± 18.0 ms). The type of capture for LOT-CRT affected the optimal VVD, with myocardial capture favouring negative VVDs (LVSP ahead). Conclusion: The optimal VVD for LOT-CRT depends on the mechanism of delayed LV activation and type of capture achieved, highlighting the importance of VVD optimization.


  • Open Access

    Electrocardiographic predictors of haemodynamic benefit from biventricular pacing: the role of atrioventricular timing measures

    by T Chakraborty, A Arnold, G Agarwal, A Naraen, N Kaza, J Mohal, K Saleh, Y Liang, A Leong, J Samways, et al.

    Background: Patients with heart failure (HF) and left bundle branch block (LBBB) are selected for biventricular pacing (BVP) cardiac resynchronisation therapy (CRT) based on their 12-lead ECG QRS complex duration (QRSd). This is due to the long-held belief that BVP delivers its beneficial effects almost exclusively by reducing ventricular dyssynchrony. Recent work (1) suggests that atrioventricular delay (AVD) shortening is another key mechanism of benefit and, therefore, that atrioventricular timing may be an important CRT substrate. The ideal 12-lead ECG measure to facilitate patient selection that yields benefits from this mechanism is yet to be elucidated. Purpose: We set out to establish whether incorporating a measure of AV delay provides additional benefit over and above using QRSd when using the 12-lead ECG to select patients who are likely to obtain haemodynamic benefit from BVP. Methods: We identified patients in sinus rhythm with HF and LBBB meeting clinical criteria for CRT who had undergone implantation of a BVP device and had also undergone high-precision haemodynamic assessment of BVP. This is where pacing is alternated between atrium-only pacing (AAI) and DDD pacing using BVP multiple times for each of a full range of AVDs during continuous beat-by-beat blood pressure recording to determine the peak haemodynamic benefit of BVP in each patient. We extracted potentially predictive, pre-specified intrinsic (unpaced) ECG features that incorporated left or right AV timing to varying extents: PR interval (PR), end-of-p-wave-to-R-wave-peak-time-V6 (Pend-RWPTV6), start-of-p-wave-to-end-of-QRS (P-QRSend) as well as conventional QRSd. Pearson's test assessed the unadjusted correlation between intrinsic ECG intervals and BVP haemodynamic benefit(∆SBP). A multiparametric regression analysis model was constructed to account for confounders and interactions between different ECG features. Results: 53 eligible patients were identified. 39 were male (73.6%), 31 had non-ischaemic aetiology (58.5%), mean LVEF was 27.6% ± SD 4.79 and mean LVEDD was 57.9± SD 9.4mm. Unadjusted correlations between intrinsic ECG features were not strong but favoured P-QRSend as a potentially predictive feature; R2 values: PR 0.28 (p=0.04), Pend-RWPTV6 0.19 (p=0.18), P-QRSend 0.27 (p=0.054), QRSd 0.045 (p=0.75). However, the multiparametric model revealed that utilising both PR interval and Pend-RWPTV6 in a predictive model showed better-adjusted correlation with BVP haemodynamic benefit (R2 0.54, p=0.04). Conclusion: ECG features that incorporate either right (PR interval) or left (Pend-RWPTV6) AVD or both (P-QRSend) are superior to QRSd for predicting haemodynamic benefit from BVP in patients with HF and LBBB. This further reinforces the role of AVD shortening as a mechanism of benefit of BVP and suggests that selecting patients on the basis of AV timing may yield more overall benefit from CRT delivered by BVP or potentially conduction system pacing.ECG interval measurementCorrelation Graphs

  • Open Access

    Comparison of clinical outcomes between transthoracic echocardiography and X-Ray guided left bundle branch pacing for bradycardia: a randomised control trial - An Editorial

    by Akriti Naraen

    Conduction system pacing has brought abut a shift in the delivery of device therapy. Although gaining growing adoption, challenges remain; one of which is higher fluoroscopy times. Yang et al describe reducing and even aiming to eliminate fluoroscopy in left bundle area pacing implantation and replacing lead visualisation with transthoracic echocardiography. This editorial reviews these methods in context with recent developments in conduction system pacing and current literature.

  • Open Access

    Therapeutic potential of conduction system pacing as a method for improving cardiac output during ventricular tachycardia

    by Daniel Keene, Alejandra A. Miyazawa, Ahran D. Arnold, Akriti Naraen, Nandita Kaza, Jagdeep S. Mohal, David C. Lefroy, Phang Boon Lim, Fu Siong Ng, Michael Koa-Wing, et al.

    Background: Ventricular tachycardia (VT) reduces cardiac output through high heart rates, loss of atrioventricular synchrony, and loss of ventricular synchrony. We studied the contribution of each mechanism and explored the potential therapeutic utility of His bundle pacing to improve cardiac output during VT. Methods: Study 1 aimed to improve the understanding of mechanisms of harm during VT (using pacing simulated VT). In 23 patients with left ventricular impairment, we recorded continuous ECG and beat-by-beat blood pressure measurements. We assessed the hemodynamic impact of heart rate and restoration of atrial and biventricular synchrony. Study 2 investigated novel pacing interventions during clinical VT by evaluating the hemodynamic effects of His bundle pacing at 5 bpm above the VT rate in 10 patients. Results: In Study 1, at progressively higher rates of simulated VT, systolic blood pressure declined: at rates of 125, 160, and 190 bpm, -22.2%, -42.0%, and -58.7%, respectively (ANOVA p < 0.0001). Restoring atrial synchrony alone had only a modest beneficial effect on systolic blood pressure (+ 3.6% at 160 bpm, p = 0.2117), restoring biventricular synchrony alone had a greater effect (+ 9.1% at 160 bpm, p = 0.242), and simultaneously restoring both significantly increased systolic blood pressure (+ 31.6% at 160 bpm, p = 0.0003). In Study 2, the mean rate of clinical VT was 143 ± 21 bpm. His bundle pacing increased systolic blood pressure by + 14.2% (p = 0.0023). In 6 of 10 patients, VT terminated with His bundle pacing. Conclusions: Restoring atrial and biventricular synchrony improved hemodynamic function in simulated and clinical VT. Conduction system pacing could improve VT tolerability and treatment. Graphical

  • Open Access

    Catheter Ablation for Ventricular Tachycardia After MI: A Reconstructed Individual Patient Data Meta-analysis of Randomised Controlled Trials

    by Rohin K Reddy, James P Howard, Yousif Ahmad, Matthew J Shun-Shin, Florentina A Simader, Alejandra A Miyazawa, Keenan Saleh, Akriti Naraen, Jack W Samways, George Katritsis, et al.

    Background: The prognostic impact of ventricular tachycardia (VT) catheter ablation is an important outstanding research question. We undertook a reconstructed individual patient data meta-analysis of randomised controlled trials comparing ablation to medical therapy in patients developing VT after MI. Methods: We systematically identified all trials comparing catheter ablation to medical therapy in patients with VT and prior MI. The prespecified primary endpoint was reconstructed individual patient assessment of all-cause mortality. Prespecified secondary endpoints included trial-level assessment of all-cause mortality, VT recurrence or defibrillator shocks and all-cause hospitalisations. Prespecified subgroup analysis was performed for ablation approaches involving only substrate modification without VT activation mapping. Sensitivity analyses were performed depending on the proportion of patients with prior MI included. Results: Eight trials, recruiting a total of 874 patients, were included. Of these 874 patients, 430 were randomised to catheter ablation and 444 were randomised to medical therapy. Catheter ablation reduced all-cause mortality compared with medical therapy when synthesising individual patient data (HR 0.63; 95% CI [0.41–0.96]; p=0.03), but not in trial-level analysis (RR 0.91; 95% CI [0.67–1.23]; p=0.53; I2=0%). Catheter ablation significantly reduced VT recurrence, defibrillator shocks and hospitalisations compared with medical therapy. Sensitivity analyses were consistent with the primary analyses. Conclusion: In patients with postinfarct VT, catheter ablation reduces mortality.


  • Open Access

    Heart Failure and Cardiac Device Therapy: A Review of Current National Institute of Health and Care Excellence and European Society of Cardiology Guidelines

    by Akriti Naraen, Dileep Duvva, Archana Rao

    Guidelines help clinicians to deliver high-quality care with therapies based on up-to-date evidence. There has been significant progress in the management of heart failure with regards to both medication and cardiac device therapy. These advances have been incorporated into national and international guidelines with varying degrees of success. This article reviews current guidance from the National Institute of Health and Care Excellence in the UK and compares this with European Society of Cardiology guidelines, and evaluates how differences between them may impact on clinical practice.


  • Open Access

    Upgrading right ventricular pacemakers to biventricular pacing or conduction system pacing: a systematic review and meta-analysis

    by Nandita Kaza, Varanand Htun, Alejandra Miyazawa, Florentina Simader, Bradley Porter, James P Howard, Ahran D Arnold, Akriti Naraen, David Luria, Michael Glikson, et al.

    Guidelines recommend patients undergoing a first pacemaker implant who have even mild left ventricular (LV) impairment should receive biventricular or conduction system pacing (CSP). There is no corresponding recommendation for patients who already have a pacemaker. We conducted a meta-analysis of randomized controlled trials (RCTs) and observational studies assessing device upgrades. The primary outcome was the echocardiographic change in LV ejection fraction (LVEF). Six RCTs (randomizing 161 patients) and 47 observational studies (2644 patients) assessing the efficacy of upgrade to biventricular pacing were eligible for analysis. Eight observational studies recruiting 217 patients of CSP upgrade were also eligible. Fourteen additional studies contributed data on complications (25 412 patients). Randomized controlled trials of biventricular pacing upgrade showed LVEF improvement of +8.4% from 35.5% and observational studies: +8.4% from 25.7%. Observational studies of left bundle branch area pacing upgrade showed +11.1% improvement from 39.0% and observational studies of His bundle pacing upgrade showed +12.7% improvement from 36.0%. New York Heart Association class decreased by −0.4, −0.8, −1.0, and −1.2, respectively. Randomized controlled trials of biventricular upgrade found improvement in Minnesota Heart Failure Score (−6.9 points) and peak oxygen uptake (+1.1 mL/kg/min). This was also seen in observational studies of biventricular upgrades (−19.67 points and +2.63 mL/kg/min, respectively). In studies of the biventricular upgrade, complication rates averaged 2% for pneumothorax, 1.4% for tamponade, and 3.7% for infection over 24 months of mean follow-up. Lead-related complications occurred in 3.3% of biventricular upgrades and 1.8% of CSP upgrades. Randomized controlled trials show significant physiological and symptomatic benefits of upgrading pacemakers to biventricular pacing. Observational studies show similar effects between biventricular pacing upgrade and CSP upgrade.